Drug development resources are limited—but early-stage decisions have an outsized impact on success.
In this webinar, you’ll learn how early-stage biosimulation and mechanistic modeling can help evaluate asset potential earlier, enabling more confident portfolio prioritization across both large pharma and emerging biotech organizations.
By applying early feasibility assessment approaches, teams can identify promising candidates sooner, reduce downstream risk, and allocate resources more effectively before entering costly IND-enabling studies.
What You’ll Learn
- How early-stage biosimulation supports portfolio prioritization decisions
- The role of mechanistic modeling in evaluating biological and pharmacological potential
- How to assess feasibility before IND-enabling studies
- Strategies for aligning scientific insight with portfolio and investment decisions
- Practical applications across both large pharma and small biotech environments
Who Should Watch
- Drug discovery and early development scientists
- Clinical pharmacologists and pharmacometricians
- Translational scientists
- R&D portfolio and program leaders
- Biotech executives and decision-makers
Speakers:
- Marc Presler, PhD, Director, QSP, Certara
- Choi Siak-Leng, Distinguished Scientist, Modeling & Simulation Local Head, Sanofi
Why This Matters
Early-stage decisions often determine downstream success or failure.
This session demonstrates how model-informed approaches can:
- Reduce costly late-stage attrition
- Improve confidence in candidate selection
- Enable data-driven portfolio trade-offs
- Accelerate timelines without increasing risk
